Does tirzepatide protect the kidneys better than dulaglutide in type 2 diabetes?
Yes. In a pre-specified exploratory kidney analysis of a randomized trial of 13,165 adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide lowered the risk of major kidney events by 23 percent compared to dulaglutide. The composite kidney outcome occurred in 6.0 percent of people on tirzepatide versus 7.6 percent on dulaglutide over a median of 4.0 years.
Both drugs are injectable medications taken once a week, and both are used to lower blood sugar in people with type 2 diabetes. Dulaglutide is a GLP-1 receptor agonist, which mimics one gut hormone that helps the body release insulin. Tirzepatide acts on two gut hormone receptors at once, GIP and GLP-1. This analysis looked at how these two drugs compared for protecting the kidneys, which are often damaged by long-standing diabetes.
What the data show
The SURPASS-CVOT trial enrolled participants at 640 sites in 30 countries. Everyone was aged 40 or older, had type 2 diabetes plus atherosclerotic cardiovascular disease, an HbA1c between 7 and 10.5 percent, and a BMI of 25 kg/m2 or greater. Researchers randomly assigned them 1:1 to either tirzepatide at up to 15 mg per week or dulaglutide at 1.5 mg per week. Neither the patients nor the doctors knew which drug each person was getting, a design that keeps the results honest. Serum creatinine, cystatin C, and urine albumin-to-creatinine ratio were checked at annual visits. At baseline, 32.0 percent of participants had microalbuminuria, 11.5 percent had macroalbuminuria, and 22.5 percent had an eGFR below 60 mL/min per 1.73 m2.
The primary composite kidney outcome had a hazard ratio of 0.77, with a 95 percent confidence interval of 0.68 to 0.88 and a P value of 0.0002, based on 396 events with tirzepatide and 498 with dulaglutide. In plain language, people on tirzepatide were about a quarter less likely to have a major kidney event than people on dulaglutide, and the result is statistically solid. The composite outcome included four serious problems: persistent macroalbuminuria, which means a large amount of protein leaking into the urine, a persistent drop in kidney filtering function of 50 percent or more, end-stage kidney disease defined as an eGFR below 15 mL/min per 1.73 m2 or the start of chronic kidney replacement therapy, and death from kidney disease.
Dr. Kumar’s Take
I find this analysis genuinely useful because it is a head-to-head comparison rather than a comparison against placebo. Both drugs already work, so the real clinical question is which one to pick, and a 23 percent lower risk of serious kidney events is a meaningful difference. The direction of benefit held across both the low-to-moderate-risk and high-risk chronic kidney disease groups, and the authors report that observations were consistent in all other subgroups examined, which suggests this is a real drug effect and not just an artifact of how the patients were grouped. I would still want longer follow-up and confirmation that the kidney advantage translates into fewer dialysis cases over a decade, but for now this gives clinicians one more reason to consider tirzepatide in patients with diabetes who also have heart disease and kidney concerns.
How the benefit played out across risk groups
The kidney advantage showed up differently depending on a patient’s starting CKD risk. In people at low to moderate risk for chronic kidney disease, events occurred in 4.0 percent on tirzepatide versus 5.6 percent on dulaglutide, a hazard ratio of 0.70 with a 95 percent confidence interval of 0.58 to 0.84 and a P value of 0.0001, and the benefit was driven mostly by fewer cases of new-onset persistent macroalbuminuria. In people who already had high CKD risk going in, events occurred in 12.2 percent versus 14.5 percent, a hazard ratio of 0.79 with a 95 percent confidence interval of 0.64 to 0.96 and a P value of 0.018, and the benefit came mostly from a slower drop in eGFR, the measure of how well the kidneys filter blood. The annual rate of eGFR decline was slower with tirzepatide by 0.29 mL/min per 1.73 m2 overall, with a 95 percent confidence interval of 0.17 to 0.41, and by 0.93 mL/min per 1.73 m2 in the high-risk group, with a 95 percent confidence interval of 0.65 to 1.22. So tirzepatide appeared to help earlier-stage patients avoid the first signs of kidney damage, while helping higher-risk patients hold onto the kidney function they still had.
Safety, limits, and caveats
Nausea, vomiting, and diarrhoea were all more common with tirzepatide than with dulaglutide, which matters when a patient has to stay on a weekly injection for years. The study was a pre-specified exploratory analysis, which is a step down from a confirmatory primary endpoint. That language matters because it tells you the researchers planned this kidney analysis ahead of time and the result is more reliable than a fishing expedition, but it is not the same as a kidney-focused trial designed to settle the question definitively. Everyone in this study also had established cardiovascular disease, so I would not assume the same size of benefit in people with diabetes who do not already have heart problems. The comparator was dulaglutide rather than placebo, so this shows that tirzepatide is better than dulaglutide for kidneys, not that dulaglutide is bad. The trial was funded by Eli Lilly and Company, and several authors are employees and shareholders of the company.
Practical Takeaways
- If you have type 2 diabetes plus heart disease and you are choosing between tirzepatide and dulaglutide, ask your doctor whether the kidney advantage shown in SURPASS-CVOT applies to your situation.
- Have your urine albumin and your eGFR checked at least once a year if you have type 2 diabetes, since rising protein in the urine is one of the earliest signs that diabetes is affecting your kidneys.
- Expect more nausea, vomiting, and diarrhoea on tirzepatide than on dulaglutide, and factor that into the decision.
- Do not stop or switch a diabetes medication on your own based on a single study, especially since cost, insurance coverage, and side effect tolerance vary widely between these two drugs.
- Keep blood pressure, blood sugar, and weight in target ranges, because no medication can fully replace the kidney protection that comes from controlling those basics.
Related Studies and Research
- Does rosuvastatin prevent heart disease in healthy people with intermediate risk? A look at the HOPE-3 trial
- Does high LDL-C help elderly people live longer? A review of 19 studies
- Pantoprazole shows no increased kidney risk in major trial
- Single-dose psilocybin vs placebo: first double-blind depression trial
FAQs
Why does type 2 diabetes damage the kidneys in the first place?
High blood sugar over many years injures the tiny blood vessels inside the kidneys that filter waste out of your blood. The first sign of trouble is often small amounts of protein leaking into the urine, which is why this trial tracked the urine albumin-to-creatinine ratio every year alongside blood tests for creatinine and cystatin C. Over time the kidneys filter less efficiently, which shows up as a falling eGFR. Kidney damage is common enough in long-standing diabetes that annual urine and blood checks are part of standard diabetes care, and catching the problem early gives you the best chance to slow it down with medication, blood pressure control, and lifestyle changes.
Is the kidney benefit from tirzepatide just because it lowers blood sugar more?
This analysis compared kidney outcomes between the two drugs and cannot pull apart the mechanism behind the difference. Tirzepatide acts on both the GIP and GLP-1 receptors while dulaglutide acts on GLP-1 alone, so any advantage could come from better metabolic control, from effects on the kidney itself, or from both together. My reading is that the practical answer for a patient does not change much either way: the outcome that was measured, fewer major kidney events over four years, is the one that matters at the bedside. Sorting out the mechanism is a question for dedicated physiology studies.
Should everyone with type 2 diabetes switch to tirzepatide for kidney protection?
No, this analysis does not support a blanket switch. The trial enrolled adults who already had atherosclerotic cardiovascular disease, so the strongest case for tirzepatide based on this data is in people who match that profile. Cost is also a real factor, since tirzepatide is expensive and insurance coverage varies, and gastrointestinal side effects were more frequent on tirzepatide in this trial. The right answer is an individual conversation with your doctor that weighs your kidney function, your heart history, your weight goals, your tolerance for side effects, and what your insurance will cover.
Bottom Line
In a large head-to-head trial, tirzepatide reduced the risk of major kidney events by 23 percent compared to dulaglutide in adults with type 2 diabetes and atherosclerotic cardiovascular disease, with 6.0 percent versus 7.6 percent of participants having an event over a median of four years. The benefit appeared in both the low-to-moderate-risk and high-risk chronic kidney disease groups, though it came through fewer new cases of macroalbuminuria in the first group and slower eGFR decline in the second. This adds kidney protection to the reasons clinicians are reaching for tirzepatide in higher-risk diabetes patients, although cost, gastrointestinal side effects, and individual circumstances still matter when choosing between the two drugs.
